F091 Granulomatous Disorders of the Adult Skin
DESCRIPTION
Come to the best session at the Academy! Granulomatous disorders represent a unique group of diseases, both noninfectious and infectious, that require clinical pathological correlation combined with a keen sense of inquiry for underlying systemic disease and pharmacologic utilization. Dermatologists need to be able to differentiate granuloma annulare, sarcoidosis, necrobiosis lipoidica, reactive granulomatous dermatitis and drug-induced granulomatous reactions, NXG, Rubella-granulomas, and more! Learn how to evaluate patients for underlying systemic diseases, and treat them with appropriate therapeutic agents.
LEARNING OBJECTIVES
Review granulomatous diseases of the skin, providing a framework to recognize different clinical presentations, interpret dermatopathology, evaluate patients for systemic disease involvement, and develop an approach to treatment
Identify characteristics of and differentiate between Granuloma Annulare, Necrobiosis Lipoidica, Sarcoidosis, Reactive Granulomatous Diseases (IGD/PNGD), Necrobiotic Xanthogranuloma, Cutaneous Crohn Disease, and more
Discuss translational advances, personalized medicine, novel therapeutics, and targeted approaches to treatments
SCHEDULE
1:00 PM
Sarcoidosis
Misha Rosenbach, MD, FAAD, Avrom Caplan, MD, FAAD, Sotonye Imadojemu, MD, FAAD, Mariam Laura Alam, MD, FAAD
1:45 PM
Novel Therapeutics, Trials, and Translational Medicine
Misha Rosenbach, MD, FAAD, Aaron Mangold, MD, FAAD, Bridget Shields, MD, FAAD
2:15 PM
Miscellaneous Granulomas: GA, IBD, NXG, RuV, and more
Caroline Nelson, MD, FAAD, Karolyn Wanat, MD, FAAD, Juliana P Berk-Krauss, MD, FAAD, Misha Rosenbach, MD, FAAD
DIRECTOR
Misha Rosenbach, MD, FAAD
SPEAKERS
Mariam Laura Alam, MD, FAAD
Juliana P Berk-Krauss, MD, FAAD
Avrom Caplan, MD, FAAD
Sotonye Imadojemu, MD, FAAD
Aaron Mangold, MD, FAAD
Caroline Nelson, MD, FAAD
Bridget Shields, MD, FAAD
Karolyn Wanat, MD, FAAD
DISCLOSURES
Mariam Laura Alam, MD, FAAD
No financial relationships exist with ineligible companies.
Juliana P Berk-Krauss, MD, FAAD
No financial relationships exist with ineligible companies.
Avrom Caplan, MD, FAAD
Novartis – Consultant (1099 relationship)(Fees); Priovant Therapeutics – Consultant (1099 relationship)(Fees), Investigator(Grants/Research Funding);
Sotonye Imadojemu, MD, FAAD
No financial relationships exist with ineligible companies.
Aaron Mangold, MD, FAAD
arGEN-X – Investigator(Grants/Research Funding); Astra Zeneca – Investigator(Grants/Research Funding); Atlas Med – Other(Patent royalties or other compensation for Intellectual Property Rights); Boehringer Ingelheim – Consultant(Honoraria); Bristol Myers Squibb – Investigator(Grants/Research Funding); clarivate – Consultant(Grants/Research Funding); Dragonfly Therapeutics – Consultant (1099 relationship)(Honoraria); Eli Lilly and Company – Investigator(Grants/Research Funding); EMD Serono – Investigator(Grants/Research Funding); Incyte Corporation – Investigator(Grants/Research Funding); Insmed – Investigator(Grants/Research Funding); Janssen Global Services, LLC – Consultant(Honoraria); Kyowa Kirin – Investigator(Grants/Research Funding); Merck – Investigator(Grants/Research Funding); miRagen Therapeutics, Inc. – Investigator(Grants/Research Funding); Novartis – Investigator(Grants/Research Funding); Pfizer Inc. – Advisory Board(Honoraria), Investigator(Grants/Research Funding); Priovant – Investigator(Grants/Research Funding); Priovant Therapeutics – Other(Patent royalties or other compensation for Intellectual Property Rights); Regeneron Pharmaceuticals, Inc. – Advisory Board(Honoraria), Investigator(Grants/Research Funding); Scitech Development – Investigator(Grants/Research Funding); Solgenix, Inc. – Advisory Board(Honoraria), Investigator(Grants/Research Funding);
Caroline Nelson, MD, FAAD
Boehringer Ingelheim – Advisory Board(Honoraria), Investigator(Grants/Research Funding);
Misha Rosenbach, MD, FAAD
J&J Innovative Medicine – Consultant(Honoraria); Merck & Co., Inc – Consultant(Honoraria); Novartis – Consultant(Honoraria); Priovant Therapeutics – Consultant (1099 relationship)(Honoraria), Investigator(Grants/Research Funding);
Bridget Shields, MD, FAAD
Arcutis Biotherapeutics – Consultant (1099 relationship)(Honoraria); Priovant Therapeutics – Consultant (1099 relationship)(Honoraria); UpToDate, Inc – Other(Honoraria);
Karolyn Wanat, MD, FAAD
No financial relationships exist with ineligible companies.